SCHEMBL14348641

SCHEMBL14348641

CC1(C)CNc2cc(NC(=O)c3ccccc3NCc3cc[n+]([O-])cc3)ccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 17/20 0.61
BRAF P15056 16/20 0.61
FLT1 P17948 3/20 0.61
KDR P35968 3/20 0.61
ABL1 P00519 2/20 0.61
EGFR P00533 2/20 0.61
CSF1R P07333 2/20 0.61
PDGFRB P09619 2/20 0.61
FLT4 P35916 2/20 0.61
CIT O14578 1/20 0.61
MAP3K7 O43318 1/20 0.61
RIPK2 O43353 1/20 0.61
STK10 O94804 1/20 0.61
MAP4K4 O95819 1/20 0.61
RAF1 P04049 1/20 0.61
LCK P06239 1/20 0.61
FYN P06241 1/20 0.61
YES1 P07947 1/20 0.61
LYN P07948 1/20 0.61
RET P07949 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5626946 0.88 KIT (0.78) KITBRAFFLT1KDRABL1
SCHEMBL4537062 0.88 KDR (0.81) KITBRAFFLT1KDRABL1
SCHEMBL14348637 0.80 NOTUM (0.41) KITBRAFFLT1KDRABL1
SCHEMBL5626575 0.78 KIT (0.57) KITBRAFFLT1KDRABL1
Motesanib SCHEMBL29354461 0.76 KDR (1.00) KITBRAFFLT1KDRABL1
Motesanib SCHEMBL187470 0.76 KDR (1.00) KITBRAFFLT1KDRABL1
Motesanib SCHEMBL445079 0.75 KDR (0.98) KITBRAFFLT1KDRABL1
SCHEMBL5626840 0.75 CIT (0.62) KITBRAFFLT1KDRABL1
SCHEMBL5627831 0.74 MEN1 (0.55) KITBRAFFLT1KDRABL1
Motesanib SCHEMBL29353301 0.74 KDR (0.95) KITBRAFFLT1KDRABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307088-B2 Substituted anthranilic amide derivatives and methods of use AMGEN INC. (US) 2007-12-11 US disclosed
US-7307088-B2 Substituted anthranilic amide derivatives and methods of use AMGEN INC. (US) 2007-12-11 US disclosed